Our previous study has confirmed that breast cancer patients with mutations at the ERBB2 TKD site exhibit heightened sensitivity to anti-HER2 therapy, suggesting that such individuals may benefit more from this treatment approach.31 In terms of oncogenic pathways, the three groups of mutant genes primarily involved in the pathway were mainly related to RTK–RAS, ERBB2, and differences in metabolic or angiogenesis pathways. This evidence concerns the gene ERBB2 and breast carcinoma.